Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...

A successful clinical trial requires an effective randomization strategy formulated by innovative thinking to meet unique demands. In a recent webinar, Solventum revealed how the eClinical platform ...

AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.

Olomorasib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Non-Small Cell Lung Cancer.

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.

Ponsegromab is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Cancer Anorexia-Cachexia Syndrome.

Lepodisiran sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase III program in Atherosclerosis.

Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).

Zelicapavir is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase II program in Respiratory Syncytial Virus (RSV) Infections.

Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy.

Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.